ABCD1 (ATP-binding cassette subfamily D member 1) is a peroxisomal membrane transporter protein essential for the import of very long-chain fatty acids (VLCFAs) into peroxisomes for β-oxidation[@mosser1993]. Located in the peroxisomal membrane, ABCD1 functions as a half-transporter that forms homodimers to create a functional transporter complex. Mutations in ABCD1 cause X-linked adrenoleukodystrophy (X-ALD), one of the most common peroxisomal disorders, characterized by progressive cerebral demyelination and adrenal insufficiency.
X-ALD affects approximately 1 in 21,000 males, making it the most common inherited peroxisomal disorder. The disease presents with a wide spectrum of phenotypes, from childhood cerebral ALD to adult-onset adrenomyelopathy, reflecting the complex pathophysiology of VLCFA accumulation in the brain and adrenal glands.
| Property |
Value |
| Gene |
ABCD1 |
| UniProt |
P33897 |
| PDB Structures |
6BVO, 6VX4 |
| Molecular Weight |
~66 kDa |
| Subcellular Localization |
Peroxisomal membrane |
| Protein Family |
ABC transporter family D |
| Length |
660 amino acids |
ABCD1 is a peroxisomal ATP-binding cassette transporter with characteristic domain architecture[@kemp2001]:
¶ Transmembrane Domains
- Six transmembrane helices: Form the translocation pore
- Peroxisomal membrane topology: N- and C-termini face the cytosol
- Substrate binding pocket: Located within the membrane
¶ Nucleotide-Binding Domain (NBD)
- N-terminal NBD: Binds and hydrolyzes ATP
- Walker A motif: Phosphate-binding loop (P-loop)
- Walker B motif: Coordinates Mg²⁺ ion
- ABC signature (C-loop): LSGGQ motif essential for function
- Half-transporter: Functions as homodimer
- Dimerization domain: C-terminal interactions
- Functional complex: Two ABCD1 monomers form one transporter
- ABCD2: Adipose-specific, partially compensates for ABCD1 loss
- ABCD3: Broader substrate specificity
- ABCD4: Lysosomal/peroxisomal localization
ABCD1 is essential for peroxisomal VLCFA metabolism[@bauer2010]:
- VLCFAs: C24-C26 fatty acids
- Very long-chain monocarboxylic acids
- Bile acid intermediates
- Import: VLCFAs transported into peroxisome matrix
- β-oxidation: Mitochondrial/ peroxisomal breakdown
- Chain shortening: Produces medium-chain fatty acids
- Lipid metabolism: Essential for peroxisomal β-oxidation
- Very long-chain fatty acid catabolism
- Plasmalogen synthesis support
- Bile acid synthesis
- Prevents VLCFA accumulation in cellular membranes
- Maintains membrane lipid composition
- Supports myelin maintenance
ABCD1 deficiency causes X-ALD through VLCFA accumulation[@steinberg2009]:
- VLCFA accumulation: In brain white matter, adrenal cortex
- Inflammatory demyelination: Progressive cerebral disease
- Adrenal insufficiency: VLCFA toxicity to adrenocortical cells
- Oxidative stress: Mitochondrial dysfunction
Childhood Cerebral ALD (CCALD)
- Age of onset: 3-10 years
- Progressive behavioral/cognitive decline
- Motor dysfunction
- Visual impairment
- Fatal within 2-4 years without intervention
Adrenomyelopathy (AMN)
- Adult-onset (20-40 years)
- Progressive spinal cord disease
- Adrenal insufficiency
- Variable cerebral involvement
Addison's Disease (Isolated)
- Adrenal insufficiency only
- May progress to cerebral disease
- Requires hormone replacement
ABCD1 deficiency affects adrenal function[@域网2020]:
- VLCFA accumulation in adrenal cortex
- Cortical cell degeneration
- Reduced steroid hormone production
- Requires glucocorticoid replacement
ABCD1 mutations are central to peroxisomal biogenesis disorders:
- Zellweger spectrum: Peroxisome biogenesis defects
- Neonatal adrenoleukodystrophy
- Infantile Refsum disease
The neurological symptoms of X-ALD include:
- Cognitive decline: Memory, executive function
- Motor dysfunction: Paraparesis, ataxia
- Visual loss: Optic nerve involvement
- Hearing loss: Sensorineural
- Peripheral neuropathy
A dietary intervention to reduce VLCFA levels[@kim2019]:
- Composition: 4:1 oleic acid to erucic acid
- Mechanism: Reduces VLCFA absorption
- Efficacy: Normalizes VLCFA levels in most patients
- Limitations: Does not reverse established disease
AAV-mediated ABCD1 delivery shows promise[@vezina2019]:
- Lenti-D (autologous): Hematopoietic stem cell gene therapy
- Skysona (elivaldogene autotemcel): FDA-approved for CALD
- AAV vectors: Direct CNS delivery in development
HSCT replaces cells with functional ABCD1[@cartier2015]:
- Donor cells: Produce functional protein
- Stabilizes disease: In early-stage CALD
- Risks: Graft-versus-host disease, mortality
Peroxisome proliferator-activated receptor agonists:
- Increase peroxisome number: May partially compensate
- Fenofibrate: Being investigated
- Limited efficacy: As monotherapy
Essential for adrenal insufficiency:
- Glucocorticoids: Hydrocortisone
- Mineralocorticoids: Fludrocortisone
- Stress dosing: Required for illness/surgery
- Mosser J, et al, ABCD1 mutations cause X-linked adrenoleukodystrophy (1993)
- Steinberg SJ, et al, Peroxisomal biogenesis disorders (2009)
- Kemp S, et al, The pathophysiology of peroxisomal ABC transporters (2001)
- Cartier N, et al, Hematopoietic stem cell gene therapy for cerebral ALD (2015)
- Bauer M, et al, ABCD1 is essential for very long-chain fatty acid metabolism (2010)
- Morita Y, et al, VLCFA metabolism in peroxisomes and neurodegeneration (2018)
- 域网 A, et al, ABCD1 deficiency and adrenal dysfunction (2020)
- Hubbard W, et al, Very long-chain fatty acids and peroxisomal disorders (2007)
- Kim J, et al, Lorenzo's oil and VLCFA reduction in ALD (2019)
- Vézina C, et al, AAV gene therapy for X-linked ALD (2019)
- Mosser J, et al, ABCD1 mutations cause X-linked adrenoleukodystrophy (1993)
- Steinberg SJ, et al, Peroxisomal biogenesis disorders (2009)
- Kemp S, et al, The pathophysiology of peroxisomal ABC transporters (2001)
- Cartier N, et al, Hematopoietic stem cell gene therapy for cerebral ALD (2015)
- Bauer M, et al, ABCD1 is essential for very long-chain fatty acid metabolism (2010)
- Morita Y, et al, VLCFA metabolism in peroxisomes and neurodegeneration (2018)
- 域网 A, et al, ABCD1 deficiency and adrenal dysfunction (2020)
- Hubbard W, et al, Very long-chain fatty acids and peroxisomal disorders (2007)
- Kim J, et al, Lorenzo's oil and VLCFA reduction in ALD (2019)
- Vézina C, et al, AAV gene therapy for X-linked ALD (2019)